Cargando…
Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation
We evaluated the prognostic value of fluorine‐18 fluorodeoxyglucose ((18)F‐FDG) positron emission tomography/computed tomography (PET/CT) in hepatocellular carcinoma (HCC). Their association with programmed death ligand 1 (PD‐L1) expression and vascular formation was further investigated. In this re...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279470/ https://www.ncbi.nlm.nih.gov/pubmed/34278175 http://dx.doi.org/10.1002/hep4.1715 |
_version_ | 1783722462254465024 |
---|---|
author | Itoh, Shinji Yoshizumi, Tomoharu Kitamura, Yoshiyuki Yugawa, Kyohei Iseda, Norifumi Shimagaki, Tomonari Nagao, Yoshihiro Toshima, Takeo Harada, Noboru Kohashi, Kenichi Baba, Shingo Ishigami, Kousei Oda, Yoshinao Mori, Masaki |
author_facet | Itoh, Shinji Yoshizumi, Tomoharu Kitamura, Yoshiyuki Yugawa, Kyohei Iseda, Norifumi Shimagaki, Tomonari Nagao, Yoshihiro Toshima, Takeo Harada, Noboru Kohashi, Kenichi Baba, Shingo Ishigami, Kousei Oda, Yoshinao Mori, Masaki |
author_sort | Itoh, Shinji |
collection | PubMed |
description | We evaluated the prognostic value of fluorine‐18 fluorodeoxyglucose ((18)F‐FDG) positron emission tomography/computed tomography (PET/CT) in hepatocellular carcinoma (HCC). Their association with programmed death ligand 1 (PD‐L1) expression and vascular formation was further investigated. In this retrospective study, using a database of 418 patients who had undergone (18)F‐FDG PET/CT before hepatic resection for HCC, immunohistochemical staining of PD‐L1, clusters of differentiation (CD) 8, CD68, and CD34 was performed. Patients with a high maximum standardized uptake value (SUVmax) on (18)F‐FDG PET/CT showed a significantly worse recurrence‐free survival (RFS) (hazard ratio [HR]: 1.500; 95% confidence interval [CI]: 1.088‐2.069; P = 0.0133) and overall survival (OS) (HR: 2.259; 95% CI: 1.276‐4.000; P = 0.0052) than patients with a low SUVmax. Logistic regression analysis showed that a high SUVmax in HCC was significantly associated with PD‐L1‐positive expression (odds ratio: 4.407; 95% CI: 2.265‐8.575; P < 0.0001). SUVmax values of HCC were associated with intratumoral CD8‐positive T‐cell counts (P = 0.0044) and CD68‐positive macrophage counts (P = 0.0061). Stratification based on SUVmax, PD‐L1 expression, and the vessels that encapsulate tumor clusters (VETC) status was also significantly associated with RFS and OS. SUVmax, VETC, and PDL1 expression were independently predictive of survival on multivariable analysis. Conclusion: Our large cohort study showed that a high SUVmax on (18)F‐FDG PET/CT is associated with a poor clinical outcome and PD‐L1 expression in patients with HCC. Additionally, stratification of patients based on the combination of SUVmax, PD‐L1 expression, and the VETC status predicts poor clinical outcome. |
format | Online Article Text |
id | pubmed-8279470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82794702021-07-15 Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation Itoh, Shinji Yoshizumi, Tomoharu Kitamura, Yoshiyuki Yugawa, Kyohei Iseda, Norifumi Shimagaki, Tomonari Nagao, Yoshihiro Toshima, Takeo Harada, Noboru Kohashi, Kenichi Baba, Shingo Ishigami, Kousei Oda, Yoshinao Mori, Masaki Hepatol Commun Original Articles We evaluated the prognostic value of fluorine‐18 fluorodeoxyglucose ((18)F‐FDG) positron emission tomography/computed tomography (PET/CT) in hepatocellular carcinoma (HCC). Their association with programmed death ligand 1 (PD‐L1) expression and vascular formation was further investigated. In this retrospective study, using a database of 418 patients who had undergone (18)F‐FDG PET/CT before hepatic resection for HCC, immunohistochemical staining of PD‐L1, clusters of differentiation (CD) 8, CD68, and CD34 was performed. Patients with a high maximum standardized uptake value (SUVmax) on (18)F‐FDG PET/CT showed a significantly worse recurrence‐free survival (RFS) (hazard ratio [HR]: 1.500; 95% confidence interval [CI]: 1.088‐2.069; P = 0.0133) and overall survival (OS) (HR: 2.259; 95% CI: 1.276‐4.000; P = 0.0052) than patients with a low SUVmax. Logistic regression analysis showed that a high SUVmax in HCC was significantly associated with PD‐L1‐positive expression (odds ratio: 4.407; 95% CI: 2.265‐8.575; P < 0.0001). SUVmax values of HCC were associated with intratumoral CD8‐positive T‐cell counts (P = 0.0044) and CD68‐positive macrophage counts (P = 0.0061). Stratification based on SUVmax, PD‐L1 expression, and the vessels that encapsulate tumor clusters (VETC) status was also significantly associated with RFS and OS. SUVmax, VETC, and PDL1 expression were independently predictive of survival on multivariable analysis. Conclusion: Our large cohort study showed that a high SUVmax on (18)F‐FDG PET/CT is associated with a poor clinical outcome and PD‐L1 expression in patients with HCC. Additionally, stratification of patients based on the combination of SUVmax, PD‐L1 expression, and the VETC status predicts poor clinical outcome. John Wiley and Sons Inc. 2021-03-26 /pmc/articles/PMC8279470/ /pubmed/34278175 http://dx.doi.org/10.1002/hep4.1715 Text en © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Itoh, Shinji Yoshizumi, Tomoharu Kitamura, Yoshiyuki Yugawa, Kyohei Iseda, Norifumi Shimagaki, Tomonari Nagao, Yoshihiro Toshima, Takeo Harada, Noboru Kohashi, Kenichi Baba, Shingo Ishigami, Kousei Oda, Yoshinao Mori, Masaki Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation |
title | Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation |
title_full | Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation |
title_fullStr | Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation |
title_full_unstemmed | Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation |
title_short | Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation |
title_sort | impact of metabolic activity in hepatocellular carcinoma: association with immune status and vascular formation |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279470/ https://www.ncbi.nlm.nih.gov/pubmed/34278175 http://dx.doi.org/10.1002/hep4.1715 |
work_keys_str_mv | AT itohshinji impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT yoshizumitomoharu impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT kitamurayoshiyuki impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT yugawakyohei impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT isedanorifumi impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT shimagakitomonari impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT nagaoyoshihiro impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT toshimatakeo impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT haradanoboru impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT kohashikenichi impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT babashingo impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT ishigamikousei impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT odayoshinao impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation AT morimasaki impactofmetabolicactivityinhepatocellularcarcinomaassociationwithimmunestatusandvascularformation |